X4 PHARMACEUTICALS is a biopharmaceutical company. Co.'s primary clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor C-X-C receptor type 4, that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, mavorixafor has the potential to provide therapeutic benefit across a variety of neutropenic disorders, including Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare, primary immunodeficiency. Co. is also developing mavorixafor in a Phase 2 clinical trial in people with certain neutropenic disorders. We show 24 historical shares outstanding datapoints in our coverage of XFOR's shares outstanding history.
Understanding the changing numbers of XFOR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like XFOR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching XFOR by allowing them to research XFOR shares outstanding history
as well as any other stock in our coverage universe. |
Free XFOR Email Alerts:
Video: Shares Outstanding Importance
